Table 2.
Association between response to CYC treatment and CYP3A4, CYP2B6, GSTM1, GSTP1, and GSTT1 polymorphisms. Significant association was only found between GSTP1 (I105V) variant and response to CYC treatment (p < 0.05).
| . | WT Responders/All Carriers [n], (%) | Heterozygous Variant Responders/All Carriers [n], (%) | Homozygous Variant Responders/All Carriers [n], (%) | p |
|---|---|---|---|---|
| CYP3A4*2 (S222P) | 14/33 (42.42%) | — | — | N/A |
| CYP3A4*1B (-289A->G) | 14/33 (42.42%) | — | — | N/A |
| CYP3A4*3 (M445T) | 14/33 (42.42%) | — | — | N/A |
| CYP2B6 (Q172H) | 12/27 (44.44%) | 2/5 (40%) | 0/1 (0%) | 0.62 |
| CYP2B6 (K262R) | 4/14 (28.57%) | 9/16 (56.25%) | 1/3 (33%) | 0.12 |
| GSTM1 (deletion) | 7/16 (43.75%) | N/A 1 | 7/17 (41.17%) | 0.88 |
| GSTP1 (I105V) | 3/14 (21.42%) | 8/13 (61.53%) | 3/6 (50%) | 0.03* |
| GSTT1 (deletion) | 9/24 (37.5%) | N/A 1 | 4/8 (50%) | 0.41 |
1 GSTM1 and GSTT1 deletion variants could only be detected in homozygous form. * The presented p value is from a post-hoc analysis assuming a dominant genetic model.